Literature DB >> 16105142

Successful treatment with adalimumab in infliximab-resistant Crohn's disease.

H Richard Barthel, Thomas Gille, Alfred Halbsguth, Martin Kramer.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16105142     DOI: 10.1111/j.1440-1746.2005.03848.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


× No keyword cloud information.
  5 in total

1.  Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab.

Authors:  Michael Marnane; Timothy Lynch; Jaqueline Scott; John Stack; Peter J Kelly
Journal:  J Neurol       Date:  2009-01-31       Impact factor: 4.849

Review 2.  Postsurgical recurrence of ileal Crohn's disease: an update on risk factors and intervention points to a central role for impaired host-microflora homeostasis.

Authors:  Michael F Cunningham; Neil G Docherty; J Calvin Coffey; John P Burke; P Ronan O'Connell
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

Review 3.  Efficacy and safety of adalimumab for the Crohn's disease: a systematic review and meta-analysis of published randomized placebo-controlled trials.

Authors:  Yun-Na Song; Ping Zheng; Jun-Hua Xiao; Zhan-Jun Lu
Journal:  Eur J Clin Pharmacol       Date:  2014-06-01       Impact factor: 2.953

4.  Cerebral Lipiodol Embolism in Hepatocellular Carcinoma Patients Treated with Transarterial Embolization/Chemoembolization.

Authors:  Hai-Jui Chu; Chung-Wei Lee; Shin-Joe Yeh; Li-Kai Tsai; Sung-Chun Tang; Jiann-Shing Jeng
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

Review 5.  A Meta-Analysis of Adalimumab for Fistula in Crohn's Disease.

Authors:  Yin-Mei Fu; Ming Chen; Ai-Jun Liao
Journal:  Gastroenterol Res Pract       Date:  2017-10-24       Impact factor: 2.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.